Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Telestroke Call Volume and Mechanical Thrombectomy after DAWN and DEFUSE 3 Trials
Cerebrovascular Disease and Interventional Neurology
P8 - Poster Session 8 (8:00 AM-9:00 AM)
4-009
To study the volume of acute telestroke calls in the post- DAWN and DEFUSE 3 era and its impact on mechanical thrombectomy rates.
After the publication of DAWN AND DEFUSE 3 trials in January 2018, the number of patients undergoing mechanical thrombectomy have increased due to the extended time window after the onset of stroke symptoms, however there is limited data on acute telestroke calls placed since then.

We analyzed data from a major telestroke network in Southeast United States looking at telestroke consults placed between January 2015 and July 2019. Calls made before and after February 2018 were divided into two groups and patient demographics, clinical characteristics and mechanical thrombectomy receipts were compared.

A total of 7,438 patients were studied. Of those, 4956 were before February 2018 and 3392 after.There was no statistical significant difference in age, race, or sex between the two groups. In the post-DAWN and DEFUSE 3 group, the median National Institute of Health Stroke Scale (NIHSS) on presentation (3 vs. 4, P<0.001) was lower, had longer symptom-onset to door time (123 vs. 85 min, P<0.001), and was found to have more stroke mimics (41% vs. 35.3%, P<0.001). The number of consults per month was higher in the post-DAWN and DEFUSE 3 group (190 vs. 103, P<0.001), however the rates of mechanical thrombectomy were similar in the two groups (3.9% vs. 3.8%, P=0.849)

Telestroke calls have significantly increased after DAWN and DEFUSE 3 trials, however we found that these calls have not increased the mechanical thrombectomy rates. This finding needs to considered as we move forward given the high demand of telestroke in the present world.

Authors/Disclosures
Ashik Shrestha, MD
PRESENTER
No disclosure on file
Sami Alkasab, MD (MUSC) Dr. Alkasab has nothing to disclose.
Eyad Almallouhi, MD (First Physician Group) Dr. Almallouhi has nothing to disclose.
Christine Holmstedt, DO The institution of Dr. Holmstedt has received research support from NIH. The institution of Dr. Holmstedt has received research support from Patient-Centered Outcomes Research Institute.